

TOXICOLOGICAL PROFILE FOR 1,4-DIOXANE

Prepared by:

SRC, Inc.

Under Contract No. 200-2004-09793

Prepared for:

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

Agency for Toxic Substances and Disease Registry

April 2012

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

UPDATE STATEMENT

A Toxicological Profile for 1,4-Dioxane, Draft for Public Comment was released in October 2007. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Environmental Medicine/Applied Toxicology Branch
1600 Clifton Road NE
Mailstop F-62
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the toxic substances each profile describes. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. A health effects summary describes the adequacy of information to determine a substance's health effects. ATSDR identifies data needs that are significant to protection of public health.

Each profile:

- (A) Examines, summarizes, and interprets available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) Determines whether adequate information on the health effects of each substance is available or being developed to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are federal, state, and local health professionals; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists also have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher J. Portier, Ph.D.
Assistant Administrator

Agency for Toxic Substances and Disease Registry

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Sharon Wilbur, M.A.
Dennis Jones, D.V.M.
John F. Risher, Ph.D
Jewell Crawford, M.D.
Brian Tencza, M.S.
ATSDR, Division of Toxicology and Environmental Medicine, Atlanta, GA

Fernando Lladós, Ph.D
Gary L. Diamond, Ph.D
Mario Citra, Ph.D.
Mark R. Osier, Ph.D
Larry O. Lockwood, Ph.D
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Applied Toxicology Branch reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for 1,4-dioxane. The panel consisted of the following members:

1. Dr. George Alexeeff, Deputy Director for Scientific Affairs, Office of Environmental Health Hazard Assessment, CAL/EPA, Oakland, California;
2. Dr. Phillip Leber, Consultant in Toxicology, Akron, Ohio;
3. Dr. Raghubir Sharma, Emeritus Fred C. Davison Distinguished Chair in Toxicology, Department of Physiology and Pharmacology, University of Georgia College of Veterinary Medicine, Athens, Georgia; and
4. Dr. Alan Stern, Chief, Bureau for Risk Analysis, Division of Science and Research, Bureau for Risk Assessment, New Jersey Department of Environmental Protection, Trenton, New Jersey.

These experts collectively have knowledge of 1,4-dioxane's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
CONTENTS.....	xiii
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT.....	1
1.1 WHAT IS 1,4-DIOXANE?	1
1.2 WHAT HAPPENS TO 1,4-DIOXANE WHEN IT ENTERS THE ENVIRONMENT?	2
1.3 HOW MIGHT I BE EXPOSED TO 1,4-DIOXANE?	2
1.4 HOW CAN 1,4-DIOXANE ENTER AND LEAVE MY BODY?.....	3
1.5 HOW CAN 1,4-DIOXANE AFFECT MY HEALTH?.....	3
1.6 HOW CAN 1,4-DIOXANE AFFECT CHILDREN?.....	4
1.7 HOW CAN FAMILIES REDUCE THEIR EXPOSURE TO 1,4-DIOXANE?	5
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,4-DIOXANE?	5
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?	6
1.10 WHERE CAN I GET MORE INFORMATION?	7
2. RELEVANCE TO PUBLIC HEALTH	9
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO 1,4-DIOXANE IN THE UNITED STATES	9
2.2 SUMMARY OF HEALTH EFFECTS	9
2.3 MINIMAL RISK LEVELS (MRLs)	14
3. HEALTH EFFECTS	29
3.1 INTRODUCTION.....	29
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE	29
3.2.1 Inhalation Exposure	31
3.2.1.1 Death.....	31
3.2.1.2 Systemic Effects.....	32
3.2.1.3 Immunological and Lymphoreticular Effects	52
3.2.1.4 Neurological Effects	52
3.2.1.5 Reproductive Effects.....	53
3.2.1.6 Developmental Effects.....	53
3.2.1.7 Cancer	54
3.2.2 Oral Exposure.....	54
3.2.2.1 Death.....	54
3.2.2.2 Systemic Effects.....	79
3.2.2.3 Immunological and Lymphoreticular Effects	85
3.2.2.4 Neurological Effects	85
3.2.2.5 Reproductive Effects.....	86
3.2.2.6 Developmental Effects.....	86
3.2.2.7 Cancer	87

3.2.3	Dermal Exposure.....	91
3.2.3.1	Death.....	91
3.2.3.2	Systemic Effects.....	94
3.2.3.3	Immunological and Lymphoreticular Effects	95
3.2.3.4	Neurological Effects	95
3.2.3.5	Reproductive Effects.....	95
3.2.3.6	Developmental Effects.....	95
3.2.3.7	Cancer	95
3.3	GENOTOXICITY	95
3.4	TOXICOKINETICS.....	99
3.4.1	Absorption.....	100
3.4.1.1	Inhalation Exposure	100
3.4.1.2	Oral Exposure	100
3.4.1.3	Dermal Exposure	101
3.4.2	Distribution	102
3.4.2.1	Inhalation Exposure	102
3.4.2.2	Oral Exposure	102
3.4.2.3	Dermal Exposure	102
3.4.2.4	Other Routes of Exposure.....	102
3.4.3	Metabolism.....	103
3.4.4	Elimination and Excretion.....	108
3.4.4.1	Inhalation Exposure	108
3.4.4.2	Oral Exposure	108
3.4.4.3	Dermal Exposure	109
3.4.4.4	Other Routes of Exposure.....	109
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	109
3.5	MECHANISMS OF ACTION	123
3.5.1	Pharmacokinetic Mechanisms.....	123
3.5.2	Mechanisms of Toxicity.....	124
3.5.3	Animal-to-Human Extrapolations	128
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	129
3.7	CHILDREN'S SUSCEPTIBILITY	130
3.8	BIOMARKERS OF EXPOSURE AND EFFECT	133
3.8.1	Biomarkers Used to Identify or Quantify Exposure to 1,4-Dioxane.....	134
3.8.2	Biomarkers Used to Characterize Effects Caused by 1,4-Dioxane.....	135
3.9	INTERACTIONS WITH OTHER CHEMICALS	135
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE.....	136
3.11	METHODS FOR REDUCING TOXIC EFFECTS.....	136
3.11.1	Reducing Peak Absorption Following Exposure.....	136
3.11.2	Reducing Body Burden	137
3.11.3	Interfering with the Mechanism of Action for Toxic Effects	137
3.12	ADEQUACY OF THE DATABASE	137
3.12.1	Existing Information on Health Effects of 1,4-Dioxane.....	137
3.12.2	Identification of Data Needs.....	138
3.12.3	Ongoing Studies	147
4.	CHEMICAL AND PHYSICAL INFORMATION.....	149
4.1	CHEMICAL IDENTITY.....	149
4.2	PHYSICAL AND CHEMICAL PROPERTIES.....	149

5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	153
5.1 PRODUCTION	153
5.2 IMPORT/EXPORT	154
5.3 USE	154
5.4 DISPOSAL	157
6. POTENTIAL FOR HUMAN EXPOSURE	159
6.1 OVERVIEW	159
6.2 RELEASES TO THE ENVIRONMENT	161
6.2.1 Air	162
6.2.2 Water	162
6.2.3 Soil	165
6.3 ENVIRONMENTAL FATE	166
6.3.1 Transport and Partitioning	166
6.3.2 Transformation and Degradation	167
6.3.2.1 Air	167
6.3.2.2 Water	168
6.3.2.3 Sediment and Soil	169
6.3.2.4 Other Media	169
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	170
6.4.1 Air	170
6.4.2 Water	172
6.4.3 Sediment and Soil	174
6.4.4 Other Environmental Media	174
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE	177
6.6 EXPOSURES OF CHILDREN	180
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	180
6.8 ADEQUACY OF THE DATABASE	181
6.8.1 Identification of Data Needs	181
6.8.2 Ongoing Studies	184
7. ANALYTICAL METHODS	185
7.1 BIOLOGICAL MATERIALS	185
7.2 ENVIRONMENTAL SAMPLES	186
7.3 OTHER SAMPLES	189
7.4 ADEQUACY OF THE DATABASE	192
7.4.1 Identification of Data Needs	194
7.4.2 Ongoing Studies	194
8. REGULATIONS, ADVISORIES, AND GUIDELINES	197
9. REFERENCES	201
10. GLOSSARY	221
APPENDICES	
A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B. USER'S GUIDE	B-1
C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS	C-1
D. HEALTH ADVISORY	D-1
E. INDEX	E-1

This page is intentionally blank.

LIST OF FIGURES

3-1. Levels of Significant Exposure to 1,4-Dioxane-Inhalation	44
3-2. Levels of Significant Exposure to 1,4-Dioxane-Oral	74
3-3. Suggested Metabolic Pathways of 1,4-Dioxane in the Rat.....	104
3-4. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance.....	111
3-5. Existing Information on Health Effects of 1,4-Dioxane.....	139
6-1. Frequency of NPL Sites with 1,4-Dioxane Contamination	160

This page is intentionally blank.

LIST OF TABLES

3-1. Levels of Significant Exposure to 1,4-Dioxane-Inhalation	33
3-2. Levels of Significant Exposure to 1,4-Dioxane-Oral	56
3-3. Levels of Significant Exposure to 1,4-Dioxane-Dermal	92
3-4. Genotoxicity of 1,4-Dioxane <i>In Vitro</i>	96
3-5. Genotoxicity of 1,4-Dioxane <i>In Vivo</i>	97
3-6. Parameters Used in the PBPK Model for 1,4-Dioxane	113
3-7. Parameters Used in the Reitz et al. (1990) PBPK Model for 1,4-Dioxane.....	116
3-8. Parameters Used in the Sweeney et al. (2008) PBPK Model for 1,4-Dioxane.....	118
3-9. Parameters Used in the Takano et al. (2010) PBPK Model for 1,4-Dioxane	122
4-1. Chemical Identity of 1,4-Dioxane	150
4-2. Physical and Chemical Properties of 1,4-Dioxane	151
5-1. Facilities that Produce, Process, or Use 1,4-Dioxane	155
6-1. Releases to the Environment from Facilities that Produce, Process, or Use 1,4-Dioxane.....	163
7-1. Analytical Methods for Determining 1,4-Dioxane in Biological Samples.....	187
7-2. Analytical Methods for Determining 1,4-Dioxane in Environmental Samples.....	190
7-3. Analytical Methods for Determining 1,4-Dioxane in Food and Food Additives, Cosmetics, and Ethoxylated Surfactant Samples.....	193
8-1. Regulations, Advisories, and Guidelines Applicable to 1,4-Dioxane	199